Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Novocure Ltd. (NVCR:NASDAQ), powered by AI.
Novocure Ltd. is currently trading at $17.49. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Novocure Ltd. on Alpha Lenz.
Novocure Ltd.'s P/E ratio is -14.3.
“Novocure Ltd. trades at a P/E of -14.3 (undervalued) with modest ROE of -38.9%.”
Ask for details →Novocure Ltd. is a medical device company specializing in innovative cancer treatment therapies. The company's primary focus is the development and commercialization of Tumor Treating Fields (TTFields) therapy, a groundbreaking method that uses electric fields to disrupt cancer cell division. This non-invasive treatment is particularly aimed at combating aggressive forms of cancer, including glioblastoma and mesothelioma. With a commitment to advancing science and technology in oncology, Novocure operates within the healthcare sector, interfacing with both medical professionals and patients. Its contributions are critically significant, as it seeks to offer alternative options where traditional treatments like chemotherapy may be less effective. Headquartered in Saint Helier, Jersey, Novocure serves a global market, striving to enhance patient outcomes through rigorous clinical research and development. Its innovative approach positions Novocure as a leader in the specialty cancer treatment domain, impacting the larger biotechnology and medical device industries."
“Novocure Ltd. trades at a P/E of -14.3 (undervalued) with modest ROE of -38.9%.”
Ask for details →Novocure Ltd. (ticker: NVCR) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 1,488 employees. Market cap is $1.9B.
The current price is $17.49 with a P/E ratio of -14.31x and P/B of 5.73x.
ROE is -38.89% and operating margin is -23.47%. Annual revenue is $655M.